Welcome to our dedicated page for Becton Dickinson & Co news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & Co stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology company whose news flow reflects activity across medical discovery, diagnostics, drug delivery and interventional care. On this page, readers can follow company-issued updates and third-party coverage related to BD’s operations, product clearances, collaborations and corporate developments.
Recent BD news highlights regulatory milestones, such as U.S. FDA 510(k) clearance for the EnCor EnCompass™ Breast Biopsy and Tissue Removal System, a multi-modality breast biopsy platform designed to support early detection and diagnosis of breast disease. Other announcements showcase BD’s role in supporting the pharmaceutical supply chain, including investments to expand production of BD Neopak™ Glass Prefillable Syringes in the United States to help meet growing demand for biologic and GLP-1 drug delivery.
Investors and observers can also track BD’s clinical and surgical innovations, including milestones with Phasix™ Mesh for hernia prevention in Europe and progress in the PREVENT trial, as well as the European launch of the BD Surgiphor™ Surgical Wound Irrigation System. In diagnostics and research, BD reports collaborations with institutions such as the University of Pennsylvania’s Institute for Immunology and Immune Health, and product updates like new IVDR-certified VIASURE assays for the BD MAX™ System and expanded configurations of BD FACSDiscover™ A8 Cell Analyzers.
Corporate governance and financial communications feature in BD’s news as well, with items such as leadership appointments in investor relations and notices regarding annual shareholder meetings. This news feed offers a centralized view of BD’s product pipeline, strategic investments, partnerships and regulatory events, providing context for how the company positions itself within the medical technology landscape.
BD (Becton, Dickinson and Company) announced its acquisition of Tepha, Inc., a developer of proprietary resorbable polymer technology, aimed at enhancing BD's surgical mesh portfolio. This acquisition facilitates vertical integration of the supply chain for BD's Phasix™ Mesh products. Tepha's GalaFLEX® products will bolster BD's capabilities in soft tissue repair and regeneration. The deal, expected to have an immaterial impact on BD's fiscal 2021 financial results, underscores the company's commitment to innovation in medical technology and enhancement of surgical solutions.
On July 23, 2021, a federal jury in Dallas found C.R. Bard's IVC blood clot filter defective, adding to a total of over $7 million in awards against the company. This marks the fourth jury ruling against Bard regarding these filters, which are linked to serious medical complications. The Recovery IVC filter caused significant issues when it fractured post-implantation. Lawyers representing affected individuals expressed intentions to continue pursuing cases until Bard acknowledges its responsibility for the product's safety risks.
BD (Becton, Dickinson and Company) has announced its acquisition of Velano Vascular, aiming to enhance patient experience through its 'One-Stick Hospital Stay' vision. This innovative approach utilizes Velano's PIVO™ device, allowing blood collection via existing PIVC lines, potentially reducing the need for multiple needlesticks. The initiative aligns with BD's long history of improving blood collection and vascular access. This acquisition supports BD's growth strategy to address unmet needs in healthcare. Financial terms of the acquisition were not disclosed.
On July 12, 2021, BD announced the appointment of David F. Melcher as non-executive chair and Claire Pomeroy as a director for its upcoming Diabetes Care spinoff, expected in H1 2022. The spinoff, subject to customary approvals, aims to establish a standalone entity poised for growth in the diabetes sector. Melcher brings extensive leadership experience, while Pomeroy offers insights from health care delivery. The transition is critical for NewCo, positioned as a major force in diabetes care.
BD (Becton, Dickinson and Company) has launched a new eCommerce platform at bdbiosciences.com aimed at enhancing the online purchasing experience for flow cytometry users. The website offers over 170 pages of new content, improved search capabilities, and customized dashboards for streamlined purchases. Available in the U.S., Canada, Europe, Australia, and New Zealand, the platform integrates with procurement systems, ensuring institutional pricing and approval processes are simplified. BD aims to empower researchers and lab managers by addressing their purchasing needs effectively.
BD (Becton, Dickinson and Company) will announce its third quarter fiscal 2021 financial results on August 5, 2021, at approximately 6:00 a.m. ET. A conference call will follow at 8:00 a.m. ET for discussions on the results, operations, and strategy. The event will be available for replay until August 12, 2021. Additionally, BD plans to host an Investor Day on November 12, 2021, with more details to be shared later. For further information, visit bd.com/investors.
BD (Becton, Dickinson and Company) announced it received 510(k) clearance from the FDA for its PeritX™ Peritoneal Catheter System to drain symptomatic, recurrent non-malignant ascites. This system, which expands on the existing PleurX™ system, allows patients to manage their condition at home, reducing hospital visits. The PeritX™ is now the first FDA-approved tunneled catheter for both malignant and non-malignant ascites, improving patient care and comfort.
Summary not available.
BD (Becton, Dickinson and Company) has partnered with USA Swimming to provide COVID-19 testing using the BD Veritor™ Plus System at various swimming events, including the U.S. Olympic Team Trials in June 2021. This initiative includes over 2,000 rapid antigen tests, supplementing existing PCR testing protocols to enhance athlete safety. BD's rapid testing technology delivers results in 15 minutes, promoting health and safety for competitors. This collaboration underscores BD's commitment to supporting athletes and ensuring safe participation in sports amidst the pandemic.
BD (Becton, Dickinson and Company) has secured pandemic orders for 2 billion injection devices to aid global COVID-19 vaccination efforts. This milestone includes commitments from over 40 countries and various NGOs. To date, BD has delivered over 900 million devices, with the remaining orders scheduled for delivery by the end of 2022. Additionally, BD plans to expand its manufacturing capacity with a $70 million project in Nebraska and invest $1.2 billion in upgrading facilities. The company was recognized at the 2021 World Vaccine Congress for its role in vaccination support.